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Abstract
Adipose tissue-derived mesenchymal stem cells (ADSC) exhibit immunosuppressive capabilities both in vitro and in vivo.
Their use for therapy in the transplant field is attractive as they could render the use of immunosuppressive drugs
unnecessary. The aim of this study was to investigate the effect of ADSC therapy on prolonging skin allograft survival.
Animals that were treated with a single injection of donor allogeneic ADSC one day after transplantation showed an
increase in donor skin graft survival by approximately one week. This improvement was associated with preserved
histological morphology, an expansion of CD4+ regulatory T cells (Treg) in draining lymph nodes, as well as heightened IL-
10 expression and down-regulated IL-17 expression. In vitro, ADSC inhibit naı¨ve CD4+ T cell proliferation and constrain Th-1
and Th-17 polarization. In summary, infusion of ADSC one day post-transplantation dramatically increases skin allograft
survival by inhibiting the Th-17 pathogenic immune response and enhancing the protective Treg immune response. Finally,
these data suggest that ADSC therapy will open new opportunities for promoting drug-free allograft survival in clinical
transplantation.
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Introduction
Adipose tissue-derived stem cells (ADSC) are an attractive
source of multipotent mesenchymal stem cells (MSC) for use in
tissue engineering and clinical applications [1]. ADSC are
characterized as a heterogeneous cell population expressing the
surface markers CD73, CD44, CD90 and CD105, but not the
hematopoietic lineage markers CD11c, CD31, CD34, CD45,
CD80 and CD86. Essentially, their plasticity and ability to
differentiate into mesenchymal origin tissues such as bone,
cartilage and fat are considered the hallmark criteria for ADSC
classification [2,3]. Their relative abundance and easy accessibility
within adult tissues make them ideal candidates for cell-based
therapies. To this end, many authors have investigated their
potential use to repair injured tissues [2–4].
In addition, several studies have shown that stem cells also
posses immunomodulatory capabilities [5–10]. MSC inhibit T
lymphocyte proliferation in mixed lymphocyte reactions (MLR)
using third party stimulator cells polyclonal stimulation [11–13].
Furthermore, the administration of MSC was found to abolish
graft-versus-host disease (GVHD) in human bone marrow
transplantation, strongly suggesting that these cells can be used
therapeutically in vivo [14].
The immunomodulation mediated by MSC requires prior
activation of the MSC by immune cells through the release of
proinflammatory cytokines such as IL-1a, IL-1b and IFN-c
[15,16]. This prior activation has been shown to be important
since IFN-c receptor-1-deficient MSC are unable to exert any
immunosuppressive effects [16]. However, once activated these
MSC can release several soluble factors, such as indoleamine 2,3-
deoxigenase (IDO), prostaglandin E2 (PGE2), inducible nitric-
oxide synthase (iNOS) and IL-6 that have immunomodulatory
effects on other cell types [12,13,17]. PGE2 was shown to have a
negative effect on the maturation of dendritic cells, driving these
cells instead to produce immunoregulatory IL-10 [18]. Similarly,
IL-6 was reported to inhibit the maturation of dendritic cells
through the down-regulation of costimulatory molecules such as
CD40, and thereby block their ability to prime T cells [19,20].
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Moreover, MSC-derived IL-6 was shown to prolong neutrophil
and lymphocyte survival [21,22]. Overall, these data show the
capacity of MSC to inhibit the immune response by restraining
dendritic cell maturation and inducing a concomitant loss of
function in NK, B and T cell compartments [23,24].
More than that, MSC can induce the expansion of regulatory
CD4+ T cells in the periphery [25,26] while also inhibiting Th-17
cell generation [27,28]. Accordingly, the use of ADSC has been
widespread since they can be harvested easily via liposuction and
then expanded in vitro. These ADSC can suppress T cell immune
responses in vivo in the GVHD model [29] as well as in
experimental models of autoimmune diseases [25,30,31]. Howev-
er, the use of ADSC to induce transplant tolerance remains
untested. Herein, we sought to study the therapeutic potential of
allogeneic ADSC in orchestrating immunoregulation and pro-
longing skin allograft survival in a mouse model.
Materials and Methods
Animals
CBA/J (H-2k) and C57BL/6 (H-2b) mice were obtained from
our Isogeneic Breeding Unit (Immunology Department, Institute
for Biomedical Science, University of Sa˜o Paulo – Brazil). All
animals were used at 8–10 weeks of age. All protocols were
conducted in adherence to the Brazilian Committee for Experi-
mental Animals and were approved by the institutional ethics
committee on animal use of the University of Sa˜o Paulo (Protocol
# 010, page 42 issue 2).
Antibodies
Anti-CD3, anti-CD4 and anti-CD25 were purchased from BD
Pharmingen; anti-CD11c, anti-CD31, anti-CD34, anti-CD40,
anti-CD44, anti-CD45, anti-CD73, anti-CD80 and anti-CD86
were purchased from BioLegend; anti-Foxp3 was purchased from
eBioscience.
Skin Transplantation
Full-thickness skin grafts 1 to 2 cm in diameter were obtained
from the tail-skin CBA/J donor mice and transplanted onto the
back of C57BL/6 recipient mice [32]. Graft rejection was defined
as the first day on which the entire graft was necrotic [32].
Isolation and Characterization of ADSC
ADSC were collected from the epididymal fat of CBA/J mice
and washed with phosphate-buffered saline (PBS). The fat was
finely minced and digested with collagenase IV (Sigma) in a 37uC
shaking water bath for 30 min. Then, the cell suspension was
centrifuged and the cell pellet was resuspended in DMEM-low
glucose (Invitrogen, EUA) supplemented with 10% fetal bovine
serum (FBS, Gibco) and penicillin/streptomycin (Invitrogen). Cells
were plated and incubated for 48 h at 37uC 5% CO2 and
subsequently washed with PBS to remove residual no-adherent red
blood cells. The adherent cells were maintained in culture for at
least 4 passages prior to use. Immunophenotype characterization
and multi-lineage differentiation potential were accessed in
agreement with previous studies [33,34].
Figure 1. Isolation and in vitro characterization of ADSC. These cells were obtained after collagenase digestion (type V) of abdominal fat tissue
from CBA/J mice and cultured in DMEM low-glucose supplemented with 10% FBS. Adherent cells were used in experiments through passage 8. Flow
cytometry analyses from passage 6 are illustrated in panel (A). FSC by SSC indicates a homogeneous population in size and granularity. These cells
were positive for CD44 and CD73 and negative for CD31, CD34, CD45, CD80 and CD86. More then 16106 events were acquired and the frequency of
positive cells was determined using FlowJo. In vitro, these cells displayed the potential to differentiate into adipogenic, chondrogenic and osteogenic
cells. ADSC were cultured in control (-) or differentiation (+) culture media, as described in the Methods. (B) Adipogenic differentiation: cells were
stained with (Oil Red O) after 10 days under adipogenic culture condition and colored orange lipid vesicles could be observed (4006). (C) Osteogenic
differentiation: cells were stained with (Von Kossa) after 28 days under osteogenic culture condition and colored calcium deposition is observed. (D)
Chondrogenic differentiation: cells were stained with (Safranin O) after 21 days under chondrogenic conditions and intense red glycosaminoglycan
staining was observed. Magnification 2006.
doi:10.1371/journal.pone.0076396.g001
ADSC and Skin Transplant
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e76396
ADSC and Bone Marrow Mononuclear Cell Adoptive
Transfers
On day +1 after skin transplantation, C57BL/6 mice were
divided into three experimental groups: animals that received a
single injection of 0.2 ml of PBS i.p. (Allo); animals that received
56105 CBA-ADSC i.p. (Allo-ADSC) or (B6-ADSC) or (Balb/c-
ADSC); animals that received 56105 bone-marrow mononuclear
cells i.p. (BMMC). In all experiments, we used 5 mice per group.
The experiments were repeated three times.
Cell Staining and Flow Cytometry
Cells obtained from the axillary lymph node were resuspended
in FACS buffer (PBS with 2% FBS) and stained for flow cytometry
analysis. To block Fc receptor-mediated binding of antibodies,
mononuclear leukocytes were resuspended in FACS buffer with
hamster anti-mouse CD16/32, clone 2.4G2 (Fc BlockTM, BD
Bioscience) for 20 minutes. These cells were then washed, placed
on ice for 30 minutes, and stained with fluorochrome-conjugated
antibodies. Cells were washed twice in buffer and reserved for
analysis. Intracellular staining for Foxp3 was performed on lymph
node cells according to the manufacturer’s procedure
(eBioscience). Intracellular staining for IFN-c and IL-17 was
performed on CD4+ T cells after activation with Leukocyte
Activation Cocktail (BD Biosciences) and following cell permea-
bilization and fixation with the BD Cytofix/Cytoperm Fixation/
Permeabilization Solution Kit (BD Biosciences) using the manu-
facturer’s protocol. For proliferation analyses, cells were stained
with 5 mM CFSE using the manufacturer’s protocol. For cell
acquisition, we used the BD FACSCanto II flow-cytometer (BD
Biosciences). Data analysis for these experiments was performed
using FlowJo software (Tree Star).
Histology
The histological analysis of the skin graft was performed by
staining 5 mm sections of paraffin embedded tissues with
hematoxylin and eosin (HE) or Sirius red.
Real-Time PCR
Skin and lymph node samples were initially snap-frozen in
liquid nitrogen. Total RNA was isolated using the TRIzol Reagent
(Invitrogen) according to manufacturer’s protocol. RNA concen-
trations were determined using NanoDrop (Thermo Scientific).
First-strand cDNAs were synthesized using MML-V reverse
transcriptase (Promega). Real-time PCR was performed using
TaqMan PCR assays (Applied Biosystems) for the following genes
of interest: IL-2 (Mm00434255_g1), IL-6 (Mm00446190_m1), IL-
10 (Mm99999062_m1), IL-17 (Mm00439619_m1), Foxp3
(Mm00475156_m1), HPRT (Mm00446968_m1), IFN-c
(Mm00801778_m1) and TGF-b (Mm03024053_m1). Quantita-
tive real-time PCR was performed via ABI PRISM 7300 Sequence
Figure 2. ADSC confer increased graft survival upon adoptive transfer. Allogeneic donor CBA/J skin allografts were transplanted onto
C57BL/6 recipients. On day +1 following surgery, recipients were separated into three experimental groups: (A) (Allo-ADSC) were injected
intraperitoneally with 56105 ADSC (n = 8); (BMMC) were injected intraperitoneally with 56105 bone marrow mononuclear cells (n = 6); (B6-ADSC)
were injected intraperitoneally with 56105 ADSC from syngeneic C57BL/6 donors; (Balb/c-ADSC) were injected intraperitoneally with 56105 ADSC
from a third party strain; (Allo) were intraperitoneally with PBS (n = 10). Isogenic skin transplants were used as controls (n = 5). Morphometric analyses
from skin histology at day 3 and 10 show: (B) collagen orientation (Sirius red), (C) neutrophil infiltration and (D) necrosis. (E) VEGF quantification was
performed by RT-PCR. (F) Numbers represent the percentage of Foxp3+ cells within gated CD4+ T cells on day 3 from axillary draining lymph nodes.
(G) RT-PCR data showing Foxp3, IFN-c and IL-2 expression in axillary draining lymph nodes and skin on the day of rejection. Data are represented as
mean 6 SEM; n= 3 independent experiments. *P,0.05.
doi:10.1371/journal.pone.0076396.g002
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Detection System (Applied Biosystems). Transcript levels were
normalized to the expression of HPRT. Analyses were performed
with the Sequence Detection Software 1.9 (SDS).
MLR-based Suppression Assay
Stimulator mature DCs (56104 cells per well) from CBA/J mice
were co-cultured with CFSE labeled naı¨ve CD4+ T cells (1.56105
cells per well) isolated from draining lymph nodes of C57BL/6
mice using a CD4+ T cell positive selection kit (Miltenyi
Biotechnology) according the manufacturer’s protocol. Cultures
were performed with or without the addition of increasing
concentrations of ADSC in a 96-well U-bottom plate. For the
contact dependent assay, cells were incubated in a 96 transwell
plate. Cells were incubated at 37uC for 96 hours. Cells were
analyzed by flow cytometer. CD4+ T cell proliferation and DC
activation marker expression were analyzed by FlowJo.
Supernatant Cytokine Measurements by BioplexH
A Bio-Plex mouse Plex cytokine assay kit (Bio-Rad laboratories)
was used in conjunction with the Bio-Plex system array reader
according to the manufacturer’s directions. The specific cytokines
(IL-4, IL-10 and IFN-c) were quantified. Standard curves for each
of the analyzed cytokines were included in each run and sample
concentrations were calculated using Bio-Plex Manager software
version 4.0. Standard curves ranged from 32,000 to 1.95 pg/mL.
Statistics
Data were analyzed using Prism5 (GraphPad Software Inc.),
and the results were expressed as mean 6 SEM. In the analysis,
comparisons were made using the Mann Whitney t test. Survival
curves were estimated by the Kaplan-Meier method and
compared with a Log Rank test. P,0.05 was considered
significant.
Results
Characterization of Adipose-derived Mesenchymal Stem
Cells
MSC can suppress immune responses both in vitro and in vivo
[9,25]. However, it is unknown whether this immunosuppressive
capacity can be exploited for therapeutic advantage through the
induction of tolerance to transplanted allografts. We therefore
tested the hypothesis that MSC can generate a tolerogenic
microenvironment imparting prolonged skin allograft survival.
To address this hypothesis, we derived in vitro MSC from
epididymal adipose tissue, which exhibit greater immunosuppres-
sive capacity as compared to MSCs from bone marrow [35]. After
three passages, the ADSC were collected and characterized by
flow cytometry for CD11c, CD31, CD34, CD44, CD45, CD73,
CD80 and CD86. As expected, the cells expressed CD44 and
CD73 but not other markers (Figure 1A). Moreover, these ADSC
exhibited characteristics of pluripotency as evidenced by their
differentiation into adipocytes, chondrocytes as well as osteocytes
under different culture conditions (Figure 1B).
Figure 3. ADSC change the cytokine milieu in vivo and block Th-17 responses. C57BL/6 mice were grafted with full thickness allogeneic tail
skin from CBA/J mice and treated or not with donor (CBA/J) ADSC. Tissues were analyzed on days 3 and 10 after transplantation. RNA was isolated
from (A) draining axillary lymph nodes and (B) skin. Gene expression of Foxp3, TGF-b, IL-10, IFN-c, IL-17 and IL-6 was assessed by quantitative RT-PCR.
Samples were normalized by expression of an endogenous housekeeping gene (HPRT). Data are represented as mean 6 SEM; n= 3 independent
experiments done in triplicate, leading to a total of $10 independent values for each point. *P,0,05.
doi:10.1371/journal.pone.0076396.g003
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ADSC Administration Prolongs Allogeneic Skin Graft
Survival
To address the question of whether ADSC can prolong
allogeneic skin graft survival, wild type C57BL/6 mice were
transplanted with fully MHC-mismatch tail skin from CBA/J mice
followed by the passive transfer of ADSC derived from donor-
matched CBA/J mice (allo-ADSC), host-matched C57Bl/6 (B6-
ADSC), or third-party Balb/c (Balb/c-ADSC). In the untreated
control group that received a single intraperitoneal injection of
PBS one day after transplantation, the median survival time
(MST) of transplanted skin grafts was 12 days. Strikingly, a single
injection of 56105 donor-matched allo-ADSC one day after
transplantation prolonged skin graft survival to an MST of 17
days. In contrast, the transfer of 56105 B6-ADSC or Balb/c-
ADSC did not show improved graft survival with an MST of 12.5
and 11 days, respectively (Figure 2A). Moreover, transfer of donor-
matched mononuclear cells from bone marrow, which has a low
fraction of MSC, failed to increase graft survival as compared to
the untreated control (MST = 12 days, Figure 2A).
Consistent with prolonged skin allograft survival, allo-ADSC
treated animals presented a healthier skin morphology with
maintenance of the collagen orientation (Figure 2B), higher
neutrophil infiltration (Figure 2C), and lower necrosis (Figure 2D)
when compared to untreated control mice 10 days post-
transplantation. These histological improvements were accompa-
nied by an elevated expression of vascular endothelial grow factor
(VEGF) as assessed by quantitative PCR (qRT-PCR) (Figure 2E)
and an increase in the frequency of CD4+Foxp3+ regulatory T
cells as determined by flow cytometry (Figure 2F) in the draining
lymph node 3 days post-transplantation.
ADSC Treatment Inhibits IL-2 and IFN-c Expression in the
Graft at the Time of Rejection
Given that skin transplants survived longer in allo-ADSC
treated mice, we hypothesized that ADSC treatment would lead to
Figure 4. ADSC are effective suppressors of CD4+ T cell proliferation in an in vitro MLR co-culture and inhibit Th-1/Th-17
polarization. (A) In an MLR culture, naı¨ve CD4+ T cells from the spleens of C57BL/6 mice were stimulated with mature dendritic cells from CBA/J
mice for 4 days in the presence or absence of different concentration of ADSC. CD4+ T cell proliferation in these cultures was analyzed by flow
cytometry. Gates represent the CFSE dilution peaks using FlowJo. (B) Expansion of cell generations was determined using FlowJo. (C) Cell
proliferation relative index was determined using FlowJo. (D) Cytokine levels for IL4, IL-10 and IFN-c from the culture supernatants were analyzed by
Bioplex. (E) Intracellular staining for IL-17 and IFN-c was performed on cultured T cells and analyzed by flow cytometry in gated CD4+ T cells using
FlowJo.
doi:10.1371/journal.pone.0076396.g004
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a decrease in the expression of T cell effector cytokines such as IL-
2 and IFN-c. Moreover, this treatment could increase in the
expression of the immunoregulatory molecules such as Foxp3, and
favor the expansion of CD4+Foxp3+ T cells. To test this
hypothesis, we initially quantified the mRNA levels of IL-2,
IFN-c and Foxp3 in the transplanted skin graft and draining
lymph nodes of allo-ADSC treated and control mice on the day of
each individual animal rejection. Interestingly, we found higher
expression of IL-2 and IFN-c in the skin graft obtained from the
untreated group as opposed to the allo-ADSC treated group
(Figure 2G). This increase in IL-2 and IFN-c expression in the skin
graft was inverted in the draining lymph nodes. However, we did
not observe any difference in Foxp3 expression between the two
groups (Figure 2G).
ADSC Treatment Increases the Expression of IL-6, IL-10,
IFN-c, and Foxp3 in the Lymph Node, but Reduces IL-17
Expression in the Skin Graft
To closely examine the expression of molecules related to
allograft tolerance and rejection, we harvested lymph nodes and
skin grafts early (day 3) and preceding allograft rejection (day 10)
post-transplantation. Interestingly, Foxp3 expression was higher in
the draining lymph nodes of allo-ADSC treated mice than control
mice on day 3 (Figure 3A), corroborating our earlier findings by
flow cytometry (Figure 2F). We also observed higher IL-6
expression in the allo-ADSC treated group on day 3, which is
not entirely unexpected due to ADSC’s known ability to secrete
high levels of IL-6 [22] (Figure 3A). Interestingly we observed
higher levels of IL-10 and IFN-c in draining lymph nodes from
allo-ADSC treated mice as compared to control mice on day 10
post-transplantation (Figure 3A). IFN-c is often correlated as an
effector cytokine produced by T cells during graft destruction, but
it is also known that IFN-c may have a suppressive function by
inducing effector cell apoptosis [36]. Furthermore, it is also known
that immunosuppression mediated by MSC depends on prior
activation by proinflammatory cytokines [15,16,24]. ADSC can
facilitate the production of IL-10 by other cells subtypes such as
Treg, monocytes and dendritic cells [18,37]. Regardless, untreated
animals expressed higher levels of IL-17 in the skin graft on days 3
and 10 as compared to allo-ADSC treated animals (Figure 3B).
ADSC Suppress Alloreactive Effector CD4+ T cell
Proliferation and Differentiation in vitro
To test the ability of the ADSC to suppress effector CD4+ T
cells in a mixed leukocyte reaction (MLR), we performed an
in vitro suppression assay. Splenic CD11c+ dendritic cells from
CBA/J mice were co-cultured with purified C57BL/6 CD4+ T
cells labeled with CFSE. After 5 days of culture, CD4+ T cells
proliferated in response to allogeneic dendritic cells as measured
by CFSE dilution (Figure 4A upper panel). The addition of
Figure 5. ADSC inhibit expression of costimulatory molecules by DC in vitro. (A) In an MLR culture, naı¨ve CD4+ T cells from the spleens of
C57BL/6 mice were co-cultured with mature dendritic cells from CBA/J mice in the presence of 16105 ADSC with contact or ADSC separated by a
permeable membrane (transwell) for 4 days. Cells were analyzed by flow cytometry. (A) Histogram showing the expression of CD40, Cd80 and CD86
[Isotype control-tinted gray; CD4+DC+ADSC black line and CD4+DC+ADSC (Transwell)]. Data were analyzed using FlowJo.
doi:10.1371/journal.pone.0076396.g005
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increasing concentrations of CBA/J ADSC inhibited the prolifer-
ation of these CD4+ T cells in a dose-dependent manner
(Figure 4A), reducing the frequency of proliferating responder
cells by up to 20%. When we co-cultured CD4+ T cells with two
different concentrations of ADSC alone, no proliferation was
observed (Figure 4A lower panel). Even though the difference in
the frequency of cells (represented by the gating) is not dramatic,
we decided to evaluate the number of cells in each generation.
Strikingly, when we analyzed the sixth and seventh generations,
the number of cells that had proliferated in response to the
allogeneic stimulus (DC+CD4) was 8-fold higher in comparison to
the groups co-cultured with ADSC (Figure 4B). Moreover, when
we measured the replication index, which determines the fold-
expansion of only responding cells, we observed a more than 2-
fold difference in proliferation (Figure 4C). Interestingly, this
inhibition was not associated with a substantial increase in IL-10
production (Figure 4D). Additionally, this inhibition of prolifera-
tion was accompanied by a complete inhibition of effector T cell
cytokine production, as demonstrated by an absolute abrogation of
IFN-c and IL-17 expression, the prototypic cytokines of Th-1 and
Th-17 cells, respectively (Figure 4E).
ADSC Suppress DC Costimulatory Molecules in vitro, in a
Contact Dependent Manner
To test whether the suppression that ADSC exerted on the
CD4+ T cell proliferation was due to an indirect effect that ADSC
had on DC, and to determine whether this effect was due to
soluble factors or was contact dependent, we performed an MLR
using a transwell system. We observed that CD11c+ cells cultured
with contact had lower levels of costimulatory molecules, such as
CD40 and CD80, as compared with CD11c+ cells cultured that
were separated from ADSC by a cytokine-permeable transwell
membrane (Figure 5A and B). We did not observe any difference
in CD86 expression (Figure 5A).
Discussion
Transplantation remains the best treatment option to correct
certain types of organ failure and tissue damage (i.e. kidney, heart,
lung, etc.). However, the long-term use of globally immunosup-
pressive drugs to prevent rejection carries with it some serious
risks, including infection and cancer due to their lack of target
specificity, as well as graft loss due to their toxicity [38]. Thus,
identifying safe methodologies to induce donor-specific allograft
survival is a top priority. One of the most attractive targets for such
therapy is Treg, which have emerged as pivotal immunoregulators
in the establishment of allograft tolerance [39–41]. While Treg
improve graft survival in several experimental models, their low
frequency under homeostatic conditions remains a roadblock to
their therapeutic use. Consequently, finding strategies to expand
Treg is essential for clinical success.
Herein, we exploited the immunoregulatory nature of ADSC to
expand Treg and prolong skin graft survival. Similar to bone
marrow-derived mesenchymal stem cells, ADSC found in adipose
tissue possess extensive proliferative capacity and the ability to
differentiate into multiple cell lineages [42,43]. Due to the relative
abundance of abdominal fat in normal individuals and the ability
to isolate MSC after liposuction, we chose to use abdominal fat as
the mesenchymal stem cell source [42]. Data from the literature
shows that ADSC are better than bone marrow derived MSC and
posses more potent immunomodulatory effects on DC [44,45].
Strikingly, when allo-ADSC were administered, they signifi-
cantly increased allograft survival compared with the untreated
animals, although this did not result in permanent allograft
tolerance. Moreover, transfer of ADSC from either a syngeneic
donor or a third party donor (Balb/c) did not improve allograft
survival, demonstrating that the prolongation of allograft survival
is donor antigen specific. This is similar to results from previous
studies showing that a donor specific transfusion (DST) into
recipients can prolong allograft survival in both humans [46] and
mice. Prolongation is enhanced when accompanied by anti-
CD40L treatment [47].
Our data illustrate the potential of ADSC to suppress immune
responses across a full MHC barrier. Furthermore, these data are
in contrast to the results we obtained through the injection of
mononuclear bone marrow cells, which we observed as having no
beneficial effect on allograft survival as compared to the untreated
controls. We presume that the low frequency of mesenchymal
stem cells in the bone marrow makes it necessary to first expand or
purify these cells in vitro prior to injection.
The fact that we do not see a long-term prolongation of the skin
graft survival with ADSC might be due to ADSC rejection.
Moreover, a recent study suggests that allogeneic MSC can be
recognized by the innate and adaptive immune systems [48].
However, more detailed studies will be needed to clarify the
precise mechanisms involved. We also believe that the immuno-
genicity of skin is an obstacle to achieving tolerance. Numerous
models have demonstrated that it is difficult to generate
permanent allograft tolerance to skin transplants [49]. In fact, it
has been noted during whole hand transplantation that the skin
was the first tissue to be rejected [50,51].
Consistent with improved allograft survival, we observed a
better histological morphology and preservation of collagen
orientation with ADSC as compared to control treatment.
Additionally, neutrophil infiltration was higher in ADSC treated
mice as compared to the untreated group. While there are studies
showing that neutrophils might contribute to allograft rejection
[52–54], Larocca et al., have also shown the importance of
neutrophil infiltration for graft acceptance in a skin transplant
model [55]. Neutrophils produce vascular-endothelial grow factor
(VEGF), an important growth factor needed for neovasculariza-
tion and tissue repair [56]. Consistent with this, we observed
increased VEGF expression in ADSC treated animals.
Additionally, we observed that the number of Treg in the
draining lymph nodes from ADSC treated animals 72 hours after
transplantation was increased as compared to untreated animals.
We believe that this effect could be through direct expansion of the
Treg pool, as it was already shown by our group that Treg
proliferate in vitro in the presence of ADSC [25]. However, this
profile was not maintained past day 10, when the number was
equivalent between both groups. The hypothesis that these cells
migrated to the graft was disproven when we failed to observe any
difference in Foxp3 expression in the graft.
Next, we observed that the expression of IL-2 and IFN-c
transcripts was higher in the draining lymph node of the ADSC
treated group, but lower in the graft of the untreated group. We
believe that the ADSC migrated to the draining lymph nodes as
our group has shown that ADSC injected into non-obese diabetic
(NOD) mice migrate to the pancreatic lymph node (PLN), thus
preventing insulitis and new onset diabetes [25]. Moreover, while
IL-2 is an important growth factor for effector T cells, it is also an
important growth factor for Treg. In vitro IL-2 and IFN-c has been
shown to be important in triggering MSCs to induce tolerance
[57]. And, while it is well established that IFN-c has an important
role during the alloimmune response against the graft [58], it is
also known that it can generate skin graft tolerance by activation of
STAT-1 in a Treg population that is dependent on IFN-c [59].
Furthermore, MSC-mediated immunosuppression is dependent
ADSC and Skin Transplant
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on IFN-c since MSC cells from IFN-c receptor-1 knockout mice
lack immunosuppressive capacity in vitro [16]. Moreover, skin
allograft acceptance has been shown to be dependent on the
presence of IFN-c, as the addition of an anti-IFN-c mAb or use of
an IFN-c knockout mouse was associated with prompt graft
rejection [32].
We also observed that the expression of IL-6 was elevated in the
ADSC treated group as compared to the untreated control group.
While IL-6 has been shown to inhibit Treg, MSC-derived IL-6
also inhibits DC maturation, decreasing their capacity to prime T
cells. IL-6 also delays apoptosis in neutrophils, providing one
possible explanation for why we see an increase in neutrophil
infiltration [19,21,22]. Thus, we hypothesize that these immature
dendritic cells could be a source of the IL-10 observed in our
studies.
Jointly with TGF-b, IL-6 drives the CD4+ T cell response to the
Th-17 cell phenotype [60]. However, in these studies, we didn’t
observe a difference in TGF-b expression between ADSC treated
and control groups. However, we did observe a decrease in IL-17
expression in the graft of ADSC treated mice, as compared to
untreated mice, 72 hours after transplantation, a difference that
persisted through day 10. IL-17 producing Th-17 cells play an
important role during inflammatory and pathogenic immune
responses [61]. IL-17 can also induce early neutrophil apoptosis
[20], offering a second possible explanation for our finding that
untreated mice have decreased neutrophil infiltration.
Finally, we observed that ADSC suppressed CD4+ T cell
proliferation and differentiation in vitro as well as expression of
costimulatory molecules by DC (mainly CD40), a process that was
contact dependent. The fact that we still observed some T cell
proliferation in the presence of ADSC, but complete abrogation of
cytokine production, is consistent with a previous publication
showing that, in the absence of CD40 signaling, CD4+ T cells
retain the capacity to proliferate but are unable to develop effector
characteristics [62]. Thus, ADSC decreased the number of
lineage-committed Th-1/Th-17 cells as evidenced by a decrease
in the production of IFN-c and IL-17 by CD4+ T cells, which is in
agreement with the literature [63].
In conclusion, we found that ADSC inhibited IL-17 production
and expanded Treg in vivo thereby generating improved allograft
survival in a skin transplant model. Prolonged transplant survival
was associated with higher expression of IL-6, IL-10 and IFN-c.
As ADSC are plentiful in patient adipose tissue, the isolation and
deployment of an ADSC therapy is an attractive methodology for
the clinical prolongation of allograft survival.
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